Adage Capital Partners’s Coherus Oncology CHRS Stock Holding History

Adage Capital Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-125,000	Closed	-$2.23M	–	764
2020 Q2	$2.23M	Sell	125,000 -25,000	-17%	-$423K	0.01%	679
2020 Q1	$2.43M	Sell	150,000 -75,000	-33%	-$1.39M	0.01%	644
2019 Q4	$4.05M	Sell	225,000 -275,000	-55%	-$5.07M	0.01%	626
2019 Q3	$10.1M	Sell	500,000 -500,000	-50%	-$9.99M	0.02%	515
2019 Q2	$22.1M	Sell	1,000,000 -250,000	-20%	-$4.34M	0.06%	347
2019 Q1	$17.1M	Buy	1,250,000 +550,000	+79%	+$7.34M	0.04%	421
2018 Q4	$6.33M	Buy	+700,000	New	+$8.1M	0.02%	579

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Adage Capital Partners's CHRS Position: Q3 2020 in Review

Adage Capital Partners sold out of Coherus Oncology (CHRS) in Q3 2020, closing a stake of 125,000 shares — an estimated $2.23M sold.

Adage Capital Partners first reported a position in CHRS in Q4 2018 and held it in 7 quarters. The position peaked at $22.1M in Q2 2019. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

Adage Capital Partners reported no remaining Coherus Oncology position as of Q3 2020 after selling out during the quarter.
Adage Capital Partners sold 125,000 Coherus Oncology shares in Q3 2020, an estimated $2.23M.
Adage Capital Partners first reported a position in Coherus Oncology in Q4 2018 and held it in 7 quarters.
Adage Capital Partners's Coherus Oncology position peaked at $22.1M in Q2 2019.
201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on Adage Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.